246 related articles for article (PubMed ID: 23186979)
1. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
3. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
[TBL] [Abstract][Full Text] [Related]
5. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal.
Tsai HC; Ho KC; Chen SH; Tseng JR; Yang LY; Lin KJ; Cheng JC; Liou MJ
Diagnostics (Basel); 2022 Jan; 12(1):. PubMed ID: 35054388
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
8. Metastatic Differentiated Thyroid Cancer Survival Is Unaffected by Mode of Preparation for
Gomes-Lima CJ; Chittimoju S; Wehbeh L; Dia S; Pagadala P; Al-Jundi M; Jhawar S; Tefera E; Mete M; Klubo-Gwiezdzinska J; Van Nostrand D; Jonklaas J; Wartofsky L; Burman KD
J Endocr Soc; 2022 May; 6(5):bvac032. PubMed ID: 35356009
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults.
Schumm MA; Pyo HQ; Kim J; Tseng CH; Yeh MW; Leung AM; Chiu HK
Clin Endocrinol (Oxf); 2021 Aug; 95(2):344-353. PubMed ID: 33704813
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human TSH versus hypothyroidism. Cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma.
Dietlein M; Busemeyer S; Kobe C; Schmidt M; Theissen P; Schicha H
Nuklearmedizin; 2010; 49(6):216-24. PubMed ID: 20877918
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
16. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
[TBL] [Abstract][Full Text] [Related]
17. Examining recombinant human TSH primed ¹³¹I therapy protocol in patients with metastatic differentiated thyroid carcinoma: comparison with the traditional thyroid hormone withdrawal protocol.
Rani D; Kaisar S; Awasare S; Kamaldeep ; Abhyankar A; Basu S
Eur J Nucl Med Mol Imaging; 2014 Sep; 41(9):1767-80. PubMed ID: 24687139
[TBL] [Abstract][Full Text] [Related]
18. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyrotropin versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer: Experience in a South Taiwanese medical center.
Tsai JR; Wu ST; Chi SY; Yang YT; Chan YC; Lim LS; Chiew YEW; Chen WC; Chen YN; Chou CK
Kaohsiung J Med Sci; 2023 Feb; 39(2):175-181. PubMed ID: 36448726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
